| 英文名稱 |
中文名稱 |
CAS號(hào) |
操作 |
| Abemaciclib metabolite M18 |
|
2704316-81-2 |
詳細(xì)
|
| Colibactin 742 |
|
2916559-62-9 |
詳細(xì)
|
| ATR-IN-29 |
|
2761193-67-1 |
詳細(xì)
|
| Clerosterol |
|
2364-23-0 |
詳細(xì)
|
| Fenoterol hydrobromide |
|
1944-12-3 |
詳細(xì)
|
| 3-[(2S)-2-amino-3-methylbutanamido]propane-1-sulfonic acid |
|
1034190-08-3 |
詳細(xì)
|
| Natalizumab |
那他珠單抗 |
189261-10-7 |
詳細(xì)
|
| KDOAM25 |
|
2230731-99-2 |
詳細(xì)
|
| Ivonescimab |
|
2428381-53-5 |
詳細(xì)
|
| 11-cis Retinoic Acid |
|
68070-35-9 |
詳細(xì)
|
| ML307 |
|
|
詳細(xì)
|
| PROTAC BTK Degrader-12 |
|
2736508-65-7 |
詳細(xì)
|
| STING agonist-29 |
|
2868261-51-0 |
詳細(xì)
|
| GNE7599 |
|
2771069-76-0 |
詳細(xì)
|
| Imdevimab |
伊姆德維馬布 |
|
詳細(xì)
|
| Duvyzat |
|
497833-27-9 |
詳細(xì)
|
| Trastuzumab emtansine |
曲妥珠單抗 |
1018448-65-1 |
詳細(xì)
|
| OG-L002 |
|
1357302-64-7 |
詳細(xì)
|
| Pembrolizumab (anti-PD-1) |
|
|
詳細(xì)
|
| Mitoquinol |
|
845959-55-9 |
詳細(xì)
|
| Tezepelumab |
特折魯單抗 |
1572943-04-4 |
詳細(xì)
|
| Trastuzumab Deruxtecan |
德盧替康-曲妥珠單抗 |
1826843-81-5 |
詳細(xì)
|
| Mepolizumab |
美泊麗單抗 |
196078-29-2 |
詳細(xì)
|
| Ocrelizumab |
奧克立珠單抗 |
637334-45-3 |
詳細(xì)
|
| Fluotrimazol |
|
31251-03-3 |
詳細(xì)
|
| Dupliumab |
度匹魯單抗 |
1190264-60-8 |
詳細(xì)
|
| Cytochalasin D/Zygosporin A/NSC 209835 |
細(xì)胞松弛素D |
22144-77-0 |
詳細(xì)
|
| Aleniglipron/GSBR-1290 |
|
2685823-26-9 |
詳細(xì)
|
| Linustedastatum |
|
2254299-48-2 |
詳細(xì)
|
| Tocilizumab |
托珠單抗 |
375823-41-9 |
詳細(xì)
|
| AG-041R |
|
159883-95-1 |
詳細(xì)
|
| Pertuzumab |
帕妥珠單抗 |
380610-27-5 |
詳細(xì)
|
| Quisinostat (JNJ-26481585) |
|
875320-29-9 |
詳細(xì)
|
| rac-5-Methyl Tetrahydropteroic Acid Sodium Salt |
|
4349-41-1 |
詳細(xì)
|
| Sarilumab |
|
1189541-98-7 |
詳細(xì)
|
| Nicorandil Impurity 16 |
|
1157-74-0 |
詳細(xì)
|
| 2'-chloro-5'-methoxy-6-methyl-[4,4'-bipyridine]-3-carboxylic acid |
2'-氯-5'-甲氧基-6-甲基-[4,4'-聯(lián)吡啶]-3-甲酸 |
2782812-46-6 |
詳細(xì)
|
| Benralizumab |
貝那利珠單抗 |
1044511-01-4 |
詳細(xì)
|
| Org 25543 |
|
363628-88-0 |
詳細(xì)
|
| iBFAR2 |
|
353484-02-3 |
詳細(xì)
|
| (9s,10s)-9,10-Dihydro-9,10-[1,2]benzenoanthracene-1,4-diol |
|
5969-70-0 |
詳細(xì)
|
| Efmoroctocog alfa |
|
1270012-79-7 |
詳細(xì)
|
| L18-MDP |
|
60398-08-5 |
詳細(xì)
|
| Glycerylphosphorylcholine |
|
563-24-6 |
詳細(xì)
|
| Thiamine Triphosphate |
|
3475-65-8 |
詳細(xì)
|
| tert-butyl 4-[5-bromo-6-[(1S)-1-methoxyethyl]pyridin-3-yl]piperazine-1-carboxylate |
|
2641824-76-0 |
詳細(xì)
|
| (R)-8-Cyclopentyl-2-((1-(2-((3R,5S)-3,5-dimethylpiperazin-1-yl)acetyl)-6-methoxyindolin-5-yl)amino)-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one |
|
3063893-60-4 |
詳細(xì)
|
| Obatoclax |
|
803712-67-6 |
詳細(xì)
|
| Ramucirumab (anti-VEGFR) |
|
947687-13-0 |
詳細(xì)
|
| (R)-2-(1-amino-2-(2,5-dibromophenyl)ethyl)-5-bromopheno |
|
1585969-24-9 |
詳細(xì)
|
| TRFS-red |
|
|
詳細(xì)
|
| Glycerophosphoinositol choline |
|
425642-32-6 |
詳細(xì)
|
| Panitumumab |
帕尼單抗 |
339177-26-3 |
詳細(xì)
|
| GDC-2394 |
|
2238822-08-5 |
詳細(xì)
|
| PF-06372222 |
|
1407592-99-7 |
詳細(xì)
|
| 3-(5-bromo-1H-indol-3-yl)-2,2-dimethylpropyl acetate |
|
2641451-61-6 |
詳細(xì)
|
| Lecanemab |
侖卡奈單抗 |
1260393-98-3 |
詳細(xì)
|
| 5-TMRIA [Tetramethylrhodamine-5-Iodoacetamide Dihydroiodide |
|
114458-99-0 |
詳細(xì)
|
| Alemtuzumab |
阿倫單抗 |
216503-57-0 |
詳細(xì)
|
| BMV109 |
|
1458731-58-2 |
詳細(xì)
|
| Benzoquinazolinone 12 |
|
1227923-91-2 |
詳細(xì)
|
| DRF-1042 |
|
200619-13-2 |
詳細(xì)
|
| SR 142948 |
|
184162-64-9 |
詳細(xì)
|
| Ledaborbactam etzadroxil |
|
1842399-68-1 |
詳細(xì)
|
| GIP/GLP-1 dual receptor agonist-1 |
|
2807481-02-1 |
詳細(xì)
|
| KRASG12D-IN-3-d3 |
|
3033638-69-3 |
詳細(xì)
|
| (S)-2-(((Benzyloxy)carbonyl)amino)-2-((tert-butoxycarbonyl)amino)acetic acid |
|
1932778-68-1 |
詳細(xì)
|
| AMrubicin hydrochloride |
|
92470-31-0 |
詳細(xì)
|
| DGN549-C |
|
2058075-34-4 |
詳細(xì)
|
| AG-7404 |
|
343565-99-1 |
詳細(xì)
|
| ASP3082 |
|
|
詳細(xì)
|
| 3-((5-Bromopyridin-2-yl)oxy) |
|
189954-65-2 |
詳細(xì)
|
| Emicizumab |
艾米珠單抗 |
1610943-06-0 |
詳細(xì)
|
| BWC0977 |
|
2254567-00-3 |
詳細(xì)
|
| Elsibucol |
|
216167-95-2 |
詳細(xì)
|
| VT02956 |
|
2999763-09-4 |
詳細(xì)
|
| 2714410-97-4 |
|
2714410-97-4 |
詳細(xì)
|
| Casirivimab |
卡西里維馬布 |
|
詳細(xì)
|
| ITK degrader 2 |
|
2858738-65-3 |
詳細(xì)
|
| 23-Oxa-OSW-1 |
|
790224-37-2 |
詳細(xì)
|
| Anti-MouseVEGFR-2Antibody(DC101) |
|
|
詳細(xì)
|
| Menin-MLL inhibitor-22 |
|
2851841-61-5 |
詳細(xì)
|
| IPG-1 AM |
|
1369302-18-0 |
詳細(xì)
|
| Epyrifenacil |
|
353292-31-6 |
詳細(xì)
|
| Aducanumab |
阿杜那單抗 |
1384260-65-4 |
詳細(xì)
|
| Dihydroxanthopterin |
|
1131-35-7 |
詳細(xì)
|
| 65141-56-2 |
|
65141-56-2 |
詳細(xì)
|
| HRS-4642 |
|
2836263-09-1 |
詳細(xì)
|
| RP03707 |
|
3030493-05-8 |
詳細(xì)
|
| Risankizumab |
瑞莎珠單抗 |
|
詳細(xì)
|
| 1110768-13-2 |
|
1110768-13-2 |
詳細(xì)
|
| Zurletrectinib/ICP-723 |
|
2403703-30-8 |
詳細(xì)
|
| Epitinib |
|
1203902-67-3 |
詳細(xì)
|
| AUR-1545 |
|
3031593-79-7 |
詳細(xì)
|
| Isoleucyl tRNA synthetase-IN-2 |
|
2494195-61-6 |
詳細(xì)
|
| (E)-2-Hydroxyoctadec-9-enoic acid |
|
56472-31-2 |
詳細(xì)
|
| KRASG12D-IN-3 |
|
3033638-63-7 |
詳細(xì)
|
| RIBI-529 |
|
216014-46-9 |
詳細(xì)
|
| Mito-TRFS |
|
|
詳細(xì)
|
| Balomenib |
|
2939850-17-4 |
詳細(xì)
|